TAN 1518B

Drug Profile

TAN 1518B

Latest Information Update: 06 Jun 2002

Price : $50

At a glance

  • Originator Takeda
  • Class Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Jun 2002 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 12 Jun 2000 No-Development-Reported for Cancer in Japan (Unknown route)
  • 21 Feb 1995 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top